Trial Profile
A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Genexol (XG) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 15 Jul 2016 New trial record
- 13 May 2015 Status changed from recruiting to completed.